Review



transfection positive control expressing gfp  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc transfection positive control expressing gfp
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Transfection Positive Control Expressing Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pMax-E2F1+(Plasmid+%2316007)/pmc12827772-30-54-61
    Average 93 stars, based on 18 article reviews
    transfection positive control expressing gfp - by Bioz Stars, 2026-11
    93/100 stars

    Images

    1) Product Images from "High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength"

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    Journal: Frontiers in Bioengineering and Biotechnology

    doi: 10.3389/fbioe.2025.1747473

    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Figure Legend Snippet: mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Techniques Used: Transfection, Control, Plasmid Preparation, Flow Cytometry

    mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Figure Legend Snippet: mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Techniques Used: Transfection

    mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Figure Legend Snippet: mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Techniques Used: Transfection

    Related Articles

    Transfection:

    Article Title: Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
    Article Snippet: Additionally, pCMV-GFP (Addgene #11153) and pCMV-CDK2 [ ] were used to transiently transfect the target cells. .. Second generation lentivirus packaging system consisting of psPAX2 (Addgene #12260), pMD2.G (Addgene #12259) and pCMV-GFP as transfection control (Addgene #11153) was used to produce lentivirus particles. ..

    Article Title: Genetic and compound screens uncover factors modulating cancer cell response to indisulam
    Article Snippet: .. Second generation lentivirus packaging system (psPAX2 [#12260; Addgene], pMD2.G [#12259; Addgene] and pCMV-GFP as transfection control [#11153; Addgene]) was used for lentiviral production. ..

    Article Title: Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
    Article Snippet: .. Second generation lentivirus packaging system (psPAX2 [#12260; Addgene], pMD2.G [#12259; Addgene] and pCMV-GFP as transfection control [#11153; Addgene]) was used for lentiviral production. ..

    Article Title: Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration (in COPD)
    Article Snippet: .. Transfection control contained 5% pEGFP puro (a gift from Michael McVoy, Addgene plasmid #45561( )), and either (i) 20% pUC19 and 75% empty modified U6_gRNA vector for the mock transfection control; (ii) 20% dSPn-VPR-mTET3del1ΔC and 75% empty modified U6_gRNA vector for the non-targeted control; or (iii) 20% dSPn-VPR-mTET3del1ΔC and 75% pooled IRF9 gRNAs (either mix 1, gRNAs 1-10, targeting the promoter (P) region of IRF9 , mix 2, gRNAs 11-19, targeting the gene body (GB) region of IRF9 or a mix containing all 19 gRNAs targeting both P and GB regions of IRF9 ). .. 24 hours later, the medium was replaced with 2 mL of prewarmed full growth medium containing 2 μg/mL of puromycin and 25 mM of sodium L-ascorbate (Sigma-Aldrich).

    Article Title: SARS-CoV-2 Spike Protein Induces Time-Dependent CTSL Upregulation in HeLa Cells and Alveolarspheres.
    Article Snippet: DNA and PEI were diluted in a ratio of 1:20 in Dulbecco's modified Eagle's medium (DMEM; Gibco, Life Technologies; #31966‐021). .. The plasmid pCMV3_SP_N‐HA_ACE2 was used to overexpress ACE2, whereas the plasmid Gamillus/pcDNA3 [31] was used as a transfection control (#124837; http://n2t.net/ addgene:124837; RRID: 124837). ..

    Article Title: In situ profiling of plasma cell clonality with image-based single-cell transcriptomics
    Article Snippet: We then created a transfection mixture for each of the desired plasmids using 100 μL of OptiMEM (Thermo, 31985062), 500 ng of each plasmid, and 1 μg of polyethylenimine (R&D Systems, 7854/100). .. Each plate also contained a single well that was transfected with a pCMV::GFP plasmid to serve as a transfection control (Addgene, 11153). .. Each plate also contained a single well that was transfected with a pCMV::GFP plasmid to serve as a transfection control (Addgene, 11153).

    Article Title: Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
    Article Snippet: Additionally, pCMV-GFP (Addgene #11153) and pCMV-CDK2 [58] were used to transiently transfect the target cells. .. Second generation lentivirus packaging system consisting of psPAX2 (Addgene #12260), pMD2.G (Addgene #12259) and pCMV-GFP as transfection control (Addgene #11153) was used to produce lentivirus particles. ..

    Control:

    Article Title: Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity
    Article Snippet: Additionally, pCMV-GFP (Addgene #11153) and pCMV-CDK2 [ ] were used to transiently transfect the target cells. .. Second generation lentivirus packaging system consisting of psPAX2 (Addgene #12260), pMD2.G (Addgene #12259) and pCMV-GFP as transfection control (Addgene #11153) was used to produce lentivirus particles. ..

    Article Title: Genetic and compound screens uncover factors modulating cancer cell response to indisulam
    Article Snippet: .. Second generation lentivirus packaging system (psPAX2 [#12260; Addgene], pMD2.G [#12259; Addgene] and pCMV-GFP as transfection control [#11153; Addgene]) was used for lentiviral production. ..

    Article Title: Genetic and compound screens uncover factors modulating cancer cell response to indisulam.
    Article Snippet: .. Second generation lentivirus packaging system (psPAX2 [#12260; Addgene], pMD2.G [#12259; Addgene] and pCMV-GFP as transfection control [#11153; Addgene]) was used for lentiviral production. ..

    Article Title: Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration (in COPD)
    Article Snippet: .. Transfection control contained 5% pEGFP puro (a gift from Michael McVoy, Addgene plasmid #45561( )), and either (i) 20% pUC19 and 75% empty modified U6_gRNA vector for the mock transfection control; (ii) 20% dSPn-VPR-mTET3del1ΔC and 75% empty modified U6_gRNA vector for the non-targeted control; or (iii) 20% dSPn-VPR-mTET3del1ΔC and 75% pooled IRF9 gRNAs (either mix 1, gRNAs 1-10, targeting the promoter (P) region of IRF9 , mix 2, gRNAs 11-19, targeting the gene body (GB) region of IRF9 or a mix containing all 19 gRNAs targeting both P and GB regions of IRF9 ). .. 24 hours later, the medium was replaced with 2 mL of prewarmed full growth medium containing 2 μg/mL of puromycin and 25 mM of sodium L-ascorbate (Sigma-Aldrich).

    Article Title: SARS-CoV-2 Spike Protein Induces Time-Dependent CTSL Upregulation in HeLa Cells and Alveolarspheres.
    Article Snippet: DNA and PEI were diluted in a ratio of 1:20 in Dulbecco's modified Eagle's medium (DMEM; Gibco, Life Technologies; #31966‐021). .. The plasmid pCMV3_SP_N‐HA_ACE2 was used to overexpress ACE2, whereas the plasmid Gamillus/pcDNA3 [31] was used as a transfection control (#124837; http://n2t.net/ addgene:124837; RRID: 124837). ..

    Article Title: In situ profiling of plasma cell clonality with image-based single-cell transcriptomics
    Article Snippet: We then created a transfection mixture for each of the desired plasmids using 100 μL of OptiMEM (Thermo, 31985062), 500 ng of each plasmid, and 1 μg of polyethylenimine (R&D Systems, 7854/100). .. Each plate also contained a single well that was transfected with a pCMV::GFP plasmid to serve as a transfection control (Addgene, 11153). .. Each plate also contained a single well that was transfected with a pCMV::GFP plasmid to serve as a transfection control (Addgene, 11153).

    Article Title: Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
    Article Snippet: Additionally, pCMV-GFP (Addgene #11153) and pCMV-CDK2 [58] were used to transiently transfect the target cells. .. Second generation lentivirus packaging system consisting of psPAX2 (Addgene #12260), pMD2.G (Addgene #12259) and pCMV-GFP as transfection control (Addgene #11153) was used to produce lentivirus particles. ..

    Plasmid Preparation:

    Article Title: Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration (in COPD)
    Article Snippet: .. Transfection control contained 5% pEGFP puro (a gift from Michael McVoy, Addgene plasmid #45561( )), and either (i) 20% pUC19 and 75% empty modified U6_gRNA vector for the mock transfection control; (ii) 20% dSPn-VPR-mTET3del1ΔC and 75% empty modified U6_gRNA vector for the non-targeted control; or (iii) 20% dSPn-VPR-mTET3del1ΔC and 75% pooled IRF9 gRNAs (either mix 1, gRNAs 1-10, targeting the promoter (P) region of IRF9 , mix 2, gRNAs 11-19, targeting the gene body (GB) region of IRF9 or a mix containing all 19 gRNAs targeting both P and GB regions of IRF9 ). .. 24 hours later, the medium was replaced with 2 mL of prewarmed full growth medium containing 2 μg/mL of puromycin and 25 mM of sodium L-ascorbate (Sigma-Aldrich).

    Article Title: SARS-CoV-2 Spike Protein Induces Time-Dependent CTSL Upregulation in HeLa Cells and Alveolarspheres.
    Article Snippet: DNA and PEI were diluted in a ratio of 1:20 in Dulbecco's modified Eagle's medium (DMEM; Gibco, Life Technologies; #31966‐021). .. The plasmid pCMV3_SP_N‐HA_ACE2 was used to overexpress ACE2, whereas the plasmid Gamillus/pcDNA3 [31] was used as a transfection control (#124837; http://n2t.net/ addgene:124837; RRID: 124837). ..

    Article Title: In situ profiling of plasma cell clonality with image-based single-cell transcriptomics
    Article Snippet: We then created a transfection mixture for each of the desired plasmids using 100 μL of OptiMEM (Thermo, 31985062), 500 ng of each plasmid, and 1 μg of polyethylenimine (R&D Systems, 7854/100). .. Each plate also contained a single well that was transfected with a pCMV::GFP plasmid to serve as a transfection control (Addgene, 11153). .. Each plate also contained a single well that was transfected with a pCMV::GFP plasmid to serve as a transfection control (Addgene, 11153).

    Modification:

    Article Title: Epigenetic deregulation of IFN and WNT pathways in AT2 cells impairs alveolar regeneration (in COPD)
    Article Snippet: .. Transfection control contained 5% pEGFP puro (a gift from Michael McVoy, Addgene plasmid #45561( )), and either (i) 20% pUC19 and 75% empty modified U6_gRNA vector for the mock transfection control; (ii) 20% dSPn-VPR-mTET3del1ΔC and 75% empty modified U6_gRNA vector for the non-targeted control; or (iii) 20% dSPn-VPR-mTET3del1ΔC and 75% pooled IRF9 gRNAs (either mix 1, gRNAs 1-10, targeting the promoter (P) region of IRF9 , mix 2, gRNAs 11-19, targeting the gene body (GB) region of IRF9 or a mix containing all 19 gRNAs targeting both P and GB regions of IRF9 ). .. 24 hours later, the medium was replaced with 2 mL of prewarmed full growth medium containing 2 μg/mL of puromycin and 25 mM of sodium L-ascorbate (Sigma-Aldrich).

    other:

    Article Title: Deep proteomic analysis of Dnmt1 mutant/hypomorphic colorectal cancer cells reveals dysregulation of epithelial–mesenchymal transition and subcellular re-localization of Beta-Catenin
    Article Snippet: 1 x 10 5 HCT116 cells were plated per well in a six well culture plate (Corning), one cells have adhered remove culture medium and replace with diluted lentiviral media (500 μl lentiviral media, 1.5 ml DMEM, 10% FCS, 5% PenStrep, 5–10μg Polybrene (Sigma)).



    Similar Products

    99
    Qiagen control sirna
    Control Sirna, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/HiPerFect+Transfection+Reagent/10__1016_slash_j__lddd__2026__100534-54-16-22
    Average 99 stars, based on 1 article reviews
    control sirna - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology scrambled shrna plasmid transfection
    Scrambled Shrna Plasmid Transfection, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/Control+shRNA+Plasmid-A/pm41957523-268-0-4
    Average 96 stars, based on 1 article reviews
    scrambled shrna plasmid transfection - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    95
    OriGene tye 563 fluorescent labeled transfection control
    Tye 563 Fluorescent Labeled Transfection Control, supplied by OriGene, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/siRNA+Related+Product/pm41579862-1027-10-15
    Average 95 stars, based on 1 article reviews
    tye 563 fluorescent labeled transfection control - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    93
    Addgene inc transfection positive control expressing gfp
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Transfection Positive Control Expressing Gfp, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/pMax-E2F1+(Plasmid+%2316007)/pmc12827772-30-54-61
    Average 93 stars, based on 1 article reviews
    transfection positive control expressing gfp - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    OriGene negative control sirna
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Negative Control Sirna, supplied by OriGene, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/siRNA+Related+Product/pm41482890-253-30-25
    Average 96 stars, based on 1 article reviews
    negative control sirna - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    93
    TargetMol sirna transfection precursor mirnas
    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability <t>post-transfection</t> (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% <t>GFP+)</t> of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.
    Sirna Transfection Precursor Mirnas, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/SiRNA+Negative+Control/pm41326795-187-30-29
    Average 93 stars, based on 1 article reviews
    sirna transfection precursor mirnas - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    96
    Santa Cruz Biotechnology non targeting control sirna
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Non Targeting Control Sirna, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/siRNA+Transfection+Reagent/pmc12748458-110-10-13
    Average 96 stars, based on 1 article reviews
    non targeting control sirna - by Bioz Stars, 2026-11
    96/100 stars
      Buy from Supplier

    99
    Qiagen non targeting nt control
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Non Targeting Nt Control, supplied by Qiagen, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/HiPerFect+Transfection+Reagent/pmc12767607-405-18-21
    Average 99 stars, based on 1 article reviews
    non targeting nt control - by Bioz Stars, 2026-11
    99/100 stars
      Buy from Supplier

    93
    Cell Signaling Technology Inc cy3 conjugated mirna transfection control
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Cy3 Conjugated Mirna Transfection Control, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/SignalSilence+Control+siRNA/pm41308698-89-0-7
    Average 93 stars, based on 1 article reviews
    cy3 conjugated mirna transfection control - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    95
    MedChemExpress si nc transfected cells
    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) <t>siRNA.</t> GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)
    Si Nc Transfected Cells, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/transfection+control/SiRNA+Negative+Control/pm41270811-73-15-30
    Average 95 stars, based on 1 article reviews
    si nc transfected cells - by Bioz Stars, 2026-11
    95/100 stars
      Buy from Supplier

    Image Search Results


    mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    doi: 10.3389/fbioe.2025.1747473

    Figure Lengend Snippet: mAb B: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey's HSD; different letters indicate p < 0.05. (D) Transfection efficiency (% GFP+) of a control plasmid (pMAX-GFP) quantified by flow cytometry. (E) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Article Snippet: CHO-S cells (R80007, Life Technologies, Waltham, MA, United States) CD CHO medium (10743029, Gibco, Thermo Fisher Scientific, Waltham, MA, United States) L-Glutamine (25030081, Thermo Fisher Scientific, Waltham, MA, United States) Freestyle MAX Transfection Reagent (16447100, Thermo Fisher Scientific, Waltham, MA, United States) OptiPRO serum free medium (12309019, Thermo Fisher Scientific, Waltham, MA, United States) Transfection positive control expressing GFP (pMax-E2F1, 16007, Addgene, Watertown, MA, United States) Solution 18 (910-3018, ChemoMetec A/S, Allerød, Denmark) NC-Slide A8 (941-0002, ChemoMetec A/S, Allerød, Denmark)

    Techniques: Transfection, Control, Plasmid Preparation, Flow Cytometry

    mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    doi: 10.3389/fbioe.2025.1747473

    Figure Lengend Snippet: mAb C: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (6), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean = SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least-squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% Cls. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Article Snippet: CHO-S cells (R80007, Life Technologies, Waltham, MA, United States) CD CHO medium (10743029, Gibco, Thermo Fisher Scientific, Waltham, MA, United States) L-Glutamine (25030081, Thermo Fisher Scientific, Waltham, MA, United States) Freestyle MAX Transfection Reagent (16447100, Thermo Fisher Scientific, Waltham, MA, United States) OptiPRO serum free medium (12309019, Thermo Fisher Scientific, Waltham, MA, United States) Transfection positive control expressing GFP (pMax-E2F1, 16007, Addgene, Watertown, MA, United States) Solution 18 (910-3018, ChemoMetec A/S, Allerød, Denmark) NC-Slide A8 (941-0002, ChemoMetec A/S, Allerød, Denmark)

    Techniques: Transfection

    mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: High-throughput optimization of antibody production in CHO cells by tuning heavy- and light-chain promoter strength

    doi: 10.3389/fbioe.2025.1747473

    Figure Lengend Snippet: mAb E: effects of LC/HC promoter strength on titer, cell density, and viability post-transfection (72 hpt), and model profiling. (A) Viability (%), (B) viable cell density (VCD; cells/mL), and (C) titer (mg/L) for all LC/HC combinations. Promoter levels: 5, 40, and 100 RPU for both LC and HC. Bars show mean ± SD (n = 2). Statistical analysis was based on one-way ANOVA with Tukey’s HSD; different letters indicate p < 0.05. (D) JMP profiler for least- squares models of titer, VCD, and viability versus LC/HC promoter strength. Left: predicted means with 95% CIs. Right: composite desirability (0-1) balancing high titer with acceptable VCD and viability. Red dashed lines mark targets/constraints.

    Article Snippet: CHO-S cells (R80007, Life Technologies, Waltham, MA, United States) CD CHO medium (10743029, Gibco, Thermo Fisher Scientific, Waltham, MA, United States) L-Glutamine (25030081, Thermo Fisher Scientific, Waltham, MA, United States) Freestyle MAX Transfection Reagent (16447100, Thermo Fisher Scientific, Waltham, MA, United States) OptiPRO serum free medium (12309019, Thermo Fisher Scientific, Waltham, MA, United States) Transfection positive control expressing GFP (pMax-E2F1, 16007, Addgene, Watertown, MA, United States) Solution 18 (910-3018, ChemoMetec A/S, Allerød, Denmark) NC-Slide A8 (941-0002, ChemoMetec A/S, Allerød, Denmark)

    Techniques: Transfection

    GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) siRNA. GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)

    Journal: Discover Oncology

    Article Title: A comprehensive pan-cancer analysis of the prognostic role and immunotherapy efficacy evaluation of Glyoxalase 1

    doi: 10.1007/s12672-025-04109-3

    Figure Lengend Snippet: GLO1 knockdown downregulates PD-L1 and enhances CD8 + T cell function in vitro. A Representative RT-qPCR of GLO1 and PD-L1 expression in A375 and 786-O cells after transfection with control (si-NC) or GLO1-specific (si-GLO1) siRNA. GAPDH served as a loading control. B , C Quantification of mRNA B and PD-L1 C protein levels normalized to GAPDH ( n = 3, * p < 0.05, ** p < 0.01). D Representative flow cytometry plots showing the percentage of CD8 + T cells apoptosis after culture in conditioned medium from si-NC or si-GLO1 A375 cells. E , F Statistical summary of TNF-a ( E ) and IFN-γ production ( F ) in CD8 + T cells cultured in conditioned medium from si-NC or si-GLO1 treated A375 and 786-O cells ( n = 3, * p < 0.05, ** p < 0.01)

    Article Snippet: Cells were transfected with GLO1-specific small interfering RNA (siRNA) or non-targeting control siRNA (Santa Cruz Biotechnology) using Lipofectamine RNAiMAX Transfection Reagent (Invitrogen) according to the manufacturer’s instructions.

    Techniques: Knockdown, Cell Function Assay, In Vitro, Quantitative RT-PCR, Expressing, Transfection, Control, Flow Cytometry, Cell Culture